Fig. 5. AI-based continuous MASH CRN scores.

a, Correlation of AI-based continuous scores with mean scores across three pathologists from EMMINENCE in the analytic performance test set. Results are shown for both AI-derived ordinal bins (blue) and pathologist-derived ordinal bins (gray). Plotted values were derived from Kendall’s tau (τ) rank correlation analysis. FDR correction of P values was performed using the Benjamini–Hochberg procedure. Filled circles indicate statistical significance, FDR-corrected P < 0.05. b, cFib versus CPA measurements in primary endpoint responders in the ATLAS clinical trial. cFib and CPA were compared between patients receiving treatment and placebo using two-sided Mann–Whitney U tests. In primary endpoint responders, continuous fibrosis scores were significantly reduced in treated patients (n = 17) versus placebo patients (n = 6; Mann–Whitney U = 20.0, P = 0.02), while proportionate area fibrosis measurements were not significantly reduced (Mann–Whitney U = 39.0, P = 0.21). cFib and CPA values for patients classified as nonresponders (n = 76), in the treatment (n = 45) or placebo (n = 31) group, are also shown. Boxes represent the 25th percentile, median and 75th percentile of the data. Whiskers extend to points that lie within 1.5-fold of the inter-quartile range of the 25th and 75th percentiles. c, Stratification of patients with BL F3 or F4 fibrosis from STELLAR-3 and STELLAR-4 trial cohorts into rapid (red) and slow (orange) progressors based on continuous score cutoffs of 3.6 and 4.6, respectively. Kaplan–Meier and Cox proportional hazards regression analyses are shown. F3: log-rank statistic = 31.0, P = 2.6 × 10⁻⁸; F4: log-rank statistic = 4.8, P = 0.028. Rounded cutoffs were chosen to maximize hazards. d, Discriminatory accuracy of AI-derived continuous scores versus ordinal scores to predict progression to cirrhosis (left) and LRE (right) in STELLAR-3 and STELLAR-4 trial cohorts. In both cases, using receiver operating characteristic analysis, the continuous AUC was significantly greater (progression to cirrhosis: 0.66 (95% CI 0.60–0.71) versus 0.59 (95% CI 0.55–0.60); progression to LRE: 0.61 (95% CI 0.51–0.71) versus 0.54 (95% CI 0.47–59)). AUC, area under the receiver operating characteristic curve; BL, baseline; FDR, false discovery rate; FPR, false positive rate; τ, Kendall’s rank correlation coefficient for ordinal scores; TPR, true positive rate.